Credit Suisse Ag Cerevel Therapeutics Holdings, Inc. Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CERE
# of Institutions
21Shares Held
5.93MCall Options Held
27.3KPut Options Held
0-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
-
Segantii Capital Management LTD1.14MShares$05.99% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA393KShares$00.95% of portfolio
-
Jane Street Group, LLC New York, NY270KShares$00.01% of portfolio
-
Tekla Capital Management LLC176KShares$00.22% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...